Wall Street brokerages forecast that Thermo Fisher Scientific (NYSE:TMO) will post earnings of $2.42 per share for the current quarter, Zacks reports. Seven analysts have made estimates for Thermo Fisher Scientific’s earnings. The lowest EPS estimate is $2.29 and the highest is $2.61. Thermo Fisher Scientific reported earnings of $2.08 per share in the same quarter last year, which indicates a positive year over year growth rate of 16.3%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Wednesday, April 25th.
According to Zacks, analysts expect that Thermo Fisher Scientific will report full-year earnings of $10.83 per share for the current financial year, with EPS estimates ranging from $10.77 to $11.01. For the next year, analysts forecast that the firm will report earnings of $12.08 per share, with EPS estimates ranging from $11.81 to $12.79. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The firm had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the previous year, the company posted $2.41 earnings per share. The business’s revenue was up 22.1% on a year-over-year basis.
In other news, CEO Marc N. Casper sold 40,000 shares of the stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total value of $8,406,400.00. Following the sale, the chief executive officer now directly owns 334,622 shares of the company’s stock, valued at $70,324,159.52. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Gregory J. Herrema sold 33,327 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $219.70, for a total value of $7,321,941.90. Following the completion of the sale, the senior vice president now directly owns 60,471 shares in the company, valued at $13,285,478.70. The disclosure for this sale can be found here. In the last quarter, insiders sold 88,827 shares of company stock valued at $19,012,672. 0.49% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Longview Partners Guernsey LTD grew its stake in shares of Thermo Fisher Scientific by 6.8% in the fourth quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock worth $926,024,000 after acquiring an additional 311,977 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Geode Capital Management LLC now owns 3,917,221 shares of the medical research company’s stock valued at $742,108,000 after buying an additional 158,961 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Thermo Fisher Scientific by 2.8% during the fourth quarter. Wells Fargo & Company MN now owns 3,189,088 shares of the medical research company’s stock valued at $605,543,000 after buying an additional 85,751 shares during the last quarter. Clearbridge Investments LLC boosted its position in shares of Thermo Fisher Scientific by 5.3% during the fourth quarter. Clearbridge Investments LLC now owns 2,862,399 shares of the medical research company’s stock valued at $543,512,000 after buying an additional 143,518 shares during the last quarter. Finally, C WorldWide Group Holding A S boosted its position in shares of Thermo Fisher Scientific by 1.9% during the fourth quarter. C WorldWide Group Holding A S now owns 2,277,108 shares of the medical research company’s stock valued at $432,378,000 after buying an additional 43,368 shares during the last quarter. 87.62% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Thermo Fisher Scientific stock traded up $1.56 during midday trading on Wednesday, reaching $215.91. 808,780 shares of the company’s stock traded hands, compared to its average volume of 1,476,189. The company has a quick ratio of 0.92, a current ratio of 1.34 and a debt-to-equity ratio of 0.74. The company has a market cap of $86,122.42, a PE ratio of 22.75, a P/E/G ratio of 1.58 and a beta of 1.14. Thermo Fisher Scientific has a 12 month low of $152.30 and a 12 month high of $226.44.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be issued a $0.17 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. The ex-dividend date is Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio is 7.17%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.